ARNA · Arena Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | - | $20.0K | - | $262.0K | - | $1.35M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $79.82M | $112.45M | $102.53M | - | $79.82M | $64.95M | $78.53M | - | $60.26M |
| SG&A | - | $30.30M | $22.88M | $26.44M | - | $19.00M | $22.88M | $26.44M | - | $20.43M |
| Total Operating Expenses | - | $194.49M | $144.39M | $131.99M | - | $98.82M | $87.82M | $104.97M | - | $80.69M |
| D&A | - | - | - | $974.0K | - | - | - | $950.0K | - | - |
| Operating Income | - | ($194.49M) | ($144.39M) | ($131.99M) | - | ($98.80M) | ($87.82M) | ($104.71M) | - | ($79.33M) |
| Interest Expense | - | $1.03M | $1.05M | $1.07M | - | $1.12M | $1.14M | $1.16M | - | $1.20M |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($196.31M) | ($146.09M) | ($118.42M) | - | ($97.44M) | ($84.93M) | ($100.21M) | - | ($72.86M) |
| EPS - Basic | - | ($3.21) | ($2.40) | ($1.98) | - | ($1.69) | ($1.61) | ($2.00) | - | ($1.46) |
| EPS - Diluted | - | ($3.21) | ($2.40) | ($1.98) | - | ($1.69) | ($1.61) | ($2.00) | - | ($1.46) |
Balance Sheet
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $224.57M | $386.65M | $514.18M | $432.98M | $219.54M | $460.14M | $550.18M | $190.43M | $243.27M | $170.88M |
| Accounts Receivable | - | - | - | - | - | - | - | $268.0K | $1.65M | $1.70M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $13.30M | $6.94M | $3.79M | $9.55M | $12.00M | $7.68M | $2.15M | $12.66M | $6.04M | $4.07M |
| Current Assets | $569.47M | $790.92M | $990.43M | $1.12B | $1.14B | $1.20B | $1.20B | $830.14M | $759.93M | $806.38M |
| Total Assets | $784.71M | $901.03M | $1.08B | $1.18B | $1.19B | $1.28B | $1.34B | $1.09B | $1.17B | $1.24B |
| Current Liabilities | $66.32M | $53.35M | $64.84M | $47.51M | $58.08M | $51.90M | $41.87M | $44.45M | $44.97M | $36.82M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $673.24M | $800.72M | $971.08M | $1.09B | $1.08B | $1.17B | $1.24B | $988.49M | $1.07B | $1.15B |
| Retained Earnings | ($2.12B) | ($1.97B) | ($1.77B) | ($1.63B) | ($1.51B) | ($1.39B) | ($1.29B) | ($1.20B) | ($1.10B) | ($1.01B) |
Cash Flow
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($119.99M) | - | - | - | ($94.05M) | - | - |
| Investing Cash Flow | - | - | - | $227.11M | - | - | - | $38.91M | - | - |
| Financing Cash Flow | - | - | - | $106.39M | - | - | - | $2.30M | - | - |
| CapEx | - | - | - | $97.0K | - | - | - | $532.0K | - | - |
| Free Cash Flow | - | - | - | ($120.09M) | - | - | - | ($94.58M) | - | - |
Ratios
| Metric | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -494010.0% | - | -39966.8% | - | -5876.7% |
| EBITDA margin | - | - | - | - | - | - | - | -39604.2% | - | - |
| Net margin | - | - | - | - | - | -487190.0% | - | -38246.9% | - | -5397.4% |
| Free cash flow margin | - | - | - | - | - | - | - | -36098.1% | - | - |
| FCF / Net income | - | - | - | 1.01 | - | - | - | 0.94 | - | - |
| R&D / Revenue | - | - | - | - | - | 399100.0% | - | 29974.4% | - | 4463.5% |
| SG&A / Revenue | - | - | - | - | - | 95010.0% | - | 10092.4% | - | 1513.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -21.8% | -13.5% | -10.0% | - | -7.6% | -6.3% | -9.2% | - | -5.9% |
| Return on equity | - | -24.5% | -15.0% | -10.9% | - | -8.3% | -6.8% | -10.1% | - | -6.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.59 | 14.82 | 15.28 | 23.61 | 19.62 | 23.17 | 28.75 | 18.67 | 16.90 | 21.90 |
| Quick ratio | 8.59 | 14.82 | 15.28 | 23.61 | 19.62 | 23.17 | 28.75 | 18.67 | 16.90 | 21.90 |
| Cash ratio | 3.39 | 7.25 | 7.93 | 9.11 | 3.78 | 8.87 | 13.14 | 4.28 | 5.41 | 4.64 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -188.6x | -137.4x | -123.0x | - | -88.2x | -76.8x | -90.0x | - | -65.9x |
| Equity multiplier | 1.17 | 1.13 | 1.12 | 1.09 | 1.10 | 1.09 | 1.08 | 1.10 | 1.10 | 1.08 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.00 | 0.00 | - | 0.00 | - | 0.00 | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | 373d | - | 459d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -100.0% | - | -100.0% | - | -98.5% | - | -100.0% | - | -44.1% |
| Revenue CAGR (3y) | - | - | - | - | - | -86.4% | - | -65.9% | - | -58.8% |
| Revenue CAGR (5y) | - | - | - | - | - | -70.6% | - | -53.7% | - | -30.2% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -96.8% | -64.4% | -26.1% | - | -24.5% | -28.1% | - | - | -120.4% |
| Net income growth (YoY) | - | -101.5% | -72.0% | -18.2% | - | -33.7% | -38.3% | - | - | -112.3% |
| EPS growth (YoY) | - | -89.9% | -49.1% | 1.0% | - | -15.8% | -29.8% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -27.0% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -37.7% | -31.6% | -21.9% | 9.9% | 0.8% | 2.1% | 3.5% | -20.5% | 76.7% | 115.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$54.0K totalCollaboration And Other Revenue$54.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ARENA PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.